Novel nanoparticles for the delivery of recombinant hepatitis B vaccine

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 4, Issue 4, 2008, Pages 311-317

  Bharali, Dhruba J ^a   Pradhan, Vandana ^b   Elkin, Galina ^b   Qi, Wu ^b   Hutson, Alan ^c   Mousa, Shaker A ^a   Thanavala, Yasmin ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Department of Biostatistics ^*  (United States)

Author keywords

Hepatitis B; Immune system; Nanoparticles; Prophylaxis; Vaccines

Indexed keywords

ANTIBODIES; ANTIGENS; DENDRIMERS; ETHYLENE GLYCOL; GLYCOLS; IMMUNOLOGY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; VACCINES;

ANTIGENICITY; BONE MARROWS; CONFOCAL IMAGING; DELIVERY SYSTEMS; DENDRITIC CELLS; GLYCOLIDE; HEPATITIS B; IMMUNE RESPONSES; IMMUNE SYSTEM; IN VITRO; LACTIDE; METHOXYPOLYETHYLENE GLYCOLS; PROPHYLAXIS; RECOMBINANT HEPATITIS B SURFACE ANTIGENS; RELEASE KINETICS; TIME POINTS;

NANOSTRUCTURES;

ANTIGEN; HEPATITIS B ANTIBODY; MACROGOL; NANOPARTICLE; POLYGLACTIN; RECOMBINANT HEPATITIS B VACCINE;

ANIMAL CELL; ANTIGENICITY; ARTICLE; CONFOCAL MICROSCOPY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN;

ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYGLACTIN 910; RECOMBINANT PROTEINS;

MUS;

EID: 55949120425     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.05.006     Document Type: Article

References (37)

1. Davis J.P. Experience with hepatitis A and B vaccines. Am J Med 118 Suppl 10A (2005) 7S-15S
2. Hadler S.C., and Margolis H.S. Epidemiology of hepatitis B virus infection. In: Ellis R.W. (Ed). Hepatitis B vaccines in clinical practice (1993), Marcel Dekker Inc, New York 141-158
3. Cheng J.F., Chisari F.V., Vu T.H., Hoffmann A.R., and Campbell T.C. Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet. Oncogene 15 (1997) 2795-2801
4. Gupta R.K., and Siber G.R. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine 13 (1995) 1263-1276
5. Clements C.J., and Griffiths E. The global impact of vaccines containing aluminum adjuvants. Vaccine 20 (2002) S24-S33
6. Trollfors B., Bergfors E., Inerot A., O'Hagan D.T., Singh M., Xie H., et al. Vaccine related itching nodules and hypersensitivity to aluminum. Vaccine 23 (2005) 975-976
7. Giudice G.D., Fragapane E., Bugarini R., Hora M., Henriksson T., Palla E., et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol 13 (2006) 1010-1013
8. Spiers I.D., Eyles J.E., Baillie L.W., Williamson E.D., and Alpar H.O. Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes. J Pharm Pharmacol 52 (2000) 1195-1201
9. Kavanagh O.V., Early B., Murray M., Foster C.J., and Adair B.M. Antigen specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(d,l-lactide-co-glycolide) microspheres. Vaccine 21 (2003) 4472-4480
10. Jiang W., Gupta R.K., Deshpande M.C., and Schwendeman S.P. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Del Rev 57 (2005) 391-410
11. Wikingsson L., and Sjoholm I. Polyacryl starch microparticles as adjuvant in oral immunization, inducing mucosal and systemic immune responses in mice. Vaccine 20 (2002) 3353-3363
12. H2 responses following nasal delivery. Vaccine 19 (2000) 1188-1198
13. Van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Verhoef J.C., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 (2003) 1400-1408
14. Kersten G., and Hirshberg H. Antigen delivery systems. Expert Rev Vaccines 3 (2004) 453-462
15. Duncan J.D., Gilley R.M., Schafer D.P., Moldoveanu Z., and Mestecky Z. Poly(lactide-co glycolide) microencapsulation of vaccines for mucosal immunization. In: Kiyono H., Ogra P.L., and McGhee J.R. (Eds). Mucosal vaccines (1996), Academic Press, San Diego 159-174
16. Kersten G.F.A., and Kaufmann G.B. Biodegradable microspheres as vehicles for antigens. In: Kaufmann S.H.E. (Ed). Concepts in vaccine development (1996), Walter de Gruyter, New York 265-302
17. Eldridge J.H., Staas J.K., Tice T.R., and Gilley R.M. Biodegradable poly (lactide-co-glycolide) microspheres. Res Immunol 143 (1992) 557-563
18. Eldridge J., Gilley R., Staas R., Moldoveanu Z., Muelbroek J., and Tice T. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbio Immunol 146 (1989) 59-66
19. Beletsi A., Panagi Z., and Avgoustaki K. Biodistribution of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock coplymers. Int J Pharm 298 (2005) 233-241
20. Davis S.S. Biomedical application of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 15 (1997) 217-224
21. Gref R., Minamitake Y., Peracchia M.T., Tubetskoy V., Torchilin V., and Langer R. Biodegradable long circulating polymeric nanospheres. Science 263 (1994) 1600-1603
22. Panagi Z., Beletsi A., Evagelatos G., Livaniou E., Ithakissios D.S., and Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 221 (2001) 143-152
23. Beletsi A., Leondiadis L., Klepetsanis P., Ithakissios D.S., and Avgoustakis K. Effect of preparative variables on the properties of PLGA-mPEG copolymers related to their application in controlled drug delivery. Int J Pharm 182 (1999) 187-197
24. Dong Y., and Feng S.S. Methoxy poly (ethylene glycol)-poly (lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25 (2004) 2843-2849
25. Gupta R.K., Chang A.C., Griffin P., Rivera R., Guo Y.Y., and Siber G.R. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid. Vaccine 15 (1997) 672-678
26. O'Hagan D.T., Jeffery H., and Davis S.S. The preparation and characterization of poly (lactide-co-glycolide) microparticles II. The entrapment of a model protein using a water-in-oil-in water emulsion solvent evaporation technique. Pharm Res 10 (1993) 362-368
27. McGee J.P., Singh M., Li X.M., Qui H., and O'Hagan D.T. The encapsulation of a model protein in poly (lactide-co-gly-colide) microparticles of various sizes; an evaluation of process reproducibility. J Microencapsul 14 (1997) 197-210
28. Thanavala Y., Kong Q.X., Richter L., Yang Y.F., Arntzen C.J., and Mason H.S. Immunization with hepatitis B surface antigen expressed in transgenic plants. Proc Natl Acad Sci U S A 98 (2001) 11539-11544
29. Thanavala Y., Mahoney M., Scott A., Pal S., Richter L., Natarajan R., et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci U S A 102 (2005) 3378-3382
30. Szmuness W., Stevens C.E., Harley E.J., Zang E.A., Oleszko W.R., William D.C., et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303 (1980) 833-841
31. Francis D.P., Hadler S.C., Thompson S.E., Maynard J.E., Ostrow D.G., Altman N., et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control Multi-Center Efficacy Trial among homosexual men. Ann Intern Med 97 (1982) 362-366
32. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315 (1986) 209-214
33. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties, and possible applications in drug delivery. Curr Drug Deliv 1 (2004) 321-333
34. Teixeira M., Alonso M.J., Pinto M.M., and Barbosa C.M. Development and characterization of PLGA nanosperes and nanocapsules containing xanthone and 3-methoxyxanthone. Eur J Pharm Biopharm 59 (2005) 491-500
35. Govender T., Stolnik S., Garnett M.C., Illum L., and Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57 (1999) 171-185
36. Dong Y., and Feng S.S. Poly (d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials 26 (2005) 6068-6076
37. Singh M., Li X.M., McGee J.P., Zamb T., Koff W., Wang C.Y., et al. Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice: evaluation of immunogenicity in mice. Vaccine 15 (1997) 475-481